EUVIMEDEUVIMED entdecken
Crossref

Combined prognostic impact of complex karyotype and KIT mutations refines risk stratification in t(8;21) acute myeloid leukemia

Lin Liu iD, Yuanfei Shi, Lu Wang, Maryam Maleki Goli iD, Parnia Ghanad iD, Shuqi Zhao, Huan Xu, Dongmei Wang iD, Lingling Qi, Huanping Wang, Zhimei Chen, Jifang Tu und 5 weitere

Cancer · 2026

DOI: 10.1002/cncr.70370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Lin Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-kit, Mutation, Translocation, Genetic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute myeloid leukemia (AML) with t(8;21) is traditionally classified as favorable‐risk; however, relapse occurs in 30%–50% of patients, indicating underlying heterogeneity. The prognostic impact and potential synergy of additional cytogenetic abnormalities (ACAs)—specifically complex karyotype (CK)—and KIT mutations remain poorly defined.

Methods

The authors conducted a retrospective cohort study of 243 adults with t(8;21) AML. CK was defined as the presence of two or more ACAs beyond t(8;21). Prognostic factors were evaluated using multivariable Cox proportional hazards models. An integrated risk stratification was developed based on CK and KIT mutation status. Minimal residual disease (MRD) was quantified via reverse transcriptase–polymerase chain reaction for the RUNX1 :: RUNX1T1 transcript.

Results

CK was an independent predictor of inferior overall survival (OS), whereas KIT mutation predicted inferior disease‐free survival (DFS) and event‐free survival (EFS) (all p < .05). Based on this integrated stratification, patients were categorized into three groups: low‐risk (CK–/ KIT –, n = 128), intermediate‐risk (CK+ or KIT +, n = 100), and high‐risk (CK+/ KIT +, n = 15). The 5‐year OS rates were 72.8%, 58.3%, and 41.6%, respectively ( p < .001). MRD positivity at the time of complete remission (CR) was associated with inferior relapse‐free survival (RFS; p = .025) and showed a trend toward independent prognostic value ( p = .068). Biologically, high‐risk cases exhibited prominent KIT driver mutations and enrichment for stem cell maintenance pathways.

Conclusions

CK and KIT mutations jointly identify a high‐risk subgroup within t(8;21) AML. This baseline genetic stratification provides a foundation for risk‐adapted therapy, with MRD assessment at CR offering complementary prognostic information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteProto-Oncogene Proteins c-kitMutationTranslocation, GeneticHumansFemalePrognosisChromosomes, Human, Pair 21Chromosomes, Human, Pair 8Middle AgedAdultMaleRetrospective StudiesNeoplasm, ResidualAgedAdolescentYoung AdultRisk AssessmentDisease-Free SurvivalCore Binding Factor Alpha 2 SubunitRUNX1 Translocation Partner 1 Protein

Stichwörter der Autor:innen

KIT mutationscomplex karyotypeprognosisrisk stratificationt(8;21) AML

Substanzen

Proto-Oncogene Proteins c-kitKIT protein, humanCore Binding Factor Alpha 2 SubunitRUNX1 Translocation Partner 1 Protein

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China.
  • Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, China.
  • Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China.
  • School of Medicine, Zhejiang University, Hangzhou, China.

ORCID-Profile: Lin Liu, Maryam Maleki Goli, Parnia Ghanad, Dongmei Wang, Jie Jin, Hongyan Tong

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, L., Shi, Y., Wang, L., Maleki Goli, M., Ghanad, P., Zhao, S., Xu, H., Wang, D., Qi, L., Wang, H., Chen, Z., Tu, J., Zhou, J., Li, M., Ruan, X., Jin, J., & Tong, H. (2026). Combined prognostic impact of complex karyotype and KIT mutations refines risk stratification in t(8;21) acute myeloid leukemia. Cancer. https://doi.org/10.1002/cncr.70370

Vancouver

Liu L, Shi Y, Wang L, Maleki Goli M, Ghanad P, Zhao S, et al. Combined prognostic impact of complex karyotype and KIT mutations refines risk stratification in t(8;21) acute myeloid leukemia. Cancer. 2026. doi:10.1002/cncr.70370

BibTeX
@article{Liu2026,
  author = {Liu, Lin and Shi, Yuanfei and Wang, Lu and Maleki Goli, Maryam and Ghanad, Parnia and Zhao, Shuqi and Xu, Huan and Wang, Dongmei and Qi, Lingling and Wang, Huanping and Chen, Zhimei and Tu, Jifang and Zhou, Junhao and Li, Mengyu and Ruan, Xiaoling and Jin, Jie and Tong, Hongyan},
  title = {Combined prognostic impact of complex karyotype and KIT mutations refines risk stratification in t(8;21) acute myeloid leukemia},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70370}
}
Kostenlos starten →